Solid Biosciences (NASDAQ:SLDB) has earned a consensus recommendation of “Hold” from the six brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $33.67.
Several analysts have recently issued reports on the company. Leerink Swann decreased their price objective on Solid Biosciences from $36.00 to $14.00 and set a “hold” rating on the stock in a report on Monday, April 2nd. JPMorgan Chase lowered Solid Biosciences from a “neutral” rating to an “underweight” rating and set a $28.00 price target on the stock. in a report on Thursday, March 15th. Chardan Capital assumed coverage on Solid Biosciences in a research report on Wednesday, February 21st. They issued a “buy” rating and a $40.00 price objective on the stock. Goldman Sachs assumed coverage on Solid Biosciences in a research report on Tuesday, February 20th. They issued a “neutral” rating and a $31.00 price objective on the stock. Finally, Nomura assumed coverage on Solid Biosciences in a research report on Tuesday, February 20th. They issued a “buy” rating and a $52.00 price objective on the stock.
In other news, Director Life Sciences Maste Perceptive acquired 1,020,000 shares of Solid Biosciences stock in a transaction dated Tuesday, January 30th. The stock was purchased at an average cost of $16.22 per share, for a total transaction of $16,544,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of NASDAQ:SLDB traded up $0.29 during mid-day trading on Thursday, reaching $10.60. 210,393 shares of the company traded hands, compared to its average volume of 385,093. The company has a market cap of $361.86 and a PE ratio of -3.58. Solid Biosciences has a 52 week low of $6.83 and a 52 week high of $33.74.
Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings results on Thursday, March 29th. The company reported ($0.84) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.29). research analysts predict that Solid Biosciences will post -1.92 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This article was reported by Zolmax and is the sole property of of Zolmax. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://zolmax.com/investing/solid-biosciences-sldb-receives-33-67-average-pt-from-analysts/2112525.html.
About Solid Biosciences
Solid Biosciences Inc, a life science company, engages in identifying and developing various therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, an adeno-associated viral vector-mediated gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles.
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.